Moody’s Investors Service (“Moody’s”) assigned a Baa2 rating to the new senior unsecured euro-denominated notes offering of AbbVie Inc. (“AbbVie”). The are no changes to AbbVie’s existing ratings including the Baa2 senior unsecured long-term ratings and the Prime-2 commercial paper rating. AbbVie’s Baa2 rating reflects the company’s large scale, high margins and robust cash flow, all supported by the lucrative Humira franchise.
blaineonline.finance.blog 